Conditions: Major Depressive Disorder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 439
Healthy volunteers: no

Brief summary:
A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of peri- and postmenopausal women with major depressive disorder

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: desvenlafaxine succinate sustained-release intervention 2: placebo
Intervention descriptions: intervention 1: 50-mg DVS SR tablets taken orally once daily. intervention 2: Placebo tablets taken orally once daily.

Protocol document: